Skip to Content

Analysts have assigned a consensus rating of “Hold” to Teladoc Health, Inc. (NYSE:TDOC).

Analysts have assigned a consensus rating of “Hold” to Teladoc Health, Inc. (NYSE:TDOC).

According to data provided by Bloomberg Ratings, the collective opinion of all thirty analysts following Teladoc Health, Inc. (NYSE: TDOC) has been compiled into a single recommendation of “Hold” for the company’s stock. In addition, one analyst recommends selling the stock, nineteen analysts recommend simply holding on to the stock, and two advocate purchasing the stock. Several brokerages have recently covered the stock, and their current average 12-month target price for the stock is $41.61 per share.
Several research organizations have expressed their interest in learning more about TDOC due to recent developments at the company. In a research note published on Wednesday, September 28, the Royal Bank of Canada announced that they would lower their target price for Teladoc Health shares from $53.00 to $35.00. This change came about as a result of recent market conditions. DA Davidson decreased their target price on shares of Teladoc Health from $45.00 to $40.00 and gave the stock a “buy” rating in a research report published on Tuesday, October 25. Credit Suisse Group assigned a “neutral” rating to the stock in a research report distributed on October 31.
Additionally, the firm lowered its price objective for Teladoc Health shares from $35.00 to $30.00. The report additionally assigned a “neutral” price target for the stock. StockNews.com advised shareholders of Teladoc Health to “sell” their company shares in a research report published on Thursday. Citigroup gave the stock a rating of “neutral” in a research note published on Tuesday, December 13. Additionally, the company lowered its price objective on Teladoc Health shares from $36.00 to $33.00. The price target was lowered, and both of these moves were made simultaneously to coincide with the change.
TDOC stock began trading for the first time on Friday for $22.29 per share. The moving average of the company’s stock price over the past 200 days is $30.92, while the moving average over the last 50 days is $27.03. The current price-to-earnings ratio for the stock is -0.36, with a beta value of 0.98; these metrics combine to give the stock a market value of $3.61 billion. A debt-to-equity ratio of 0.25, a current ratio of 3.13, a quick ratio of 2.99, and a current ratio of 3.13 are all present. The current ratio is 3.13. Throughout the previous year, the price of Teladoc Health fluctuated at various points, ranging from $21.60 to 88.11 dollars.
The most recent quarterly results report for Teladoc Health (NYSE: TDOC) was made public on October 26, which was a Wednesday. The healthcare provider reported earnings per share (EPS) for the quarter at $0.45, which was $0.14 higher than the average estimate of $0.59. In addition, the company’s quarterly sales were significantly higher than the $609.45 million analysts anticipated they would bring in, coming in at a total of $611.40 million instead. When the most recent financials were compiled, Teladoc Health had a return on equity of 2.47% and a negative net margin of 424.40%. As a result, equity research experts predicted that Teladoc Health would incur a loss of $1.4 per share during the current fiscal year, which began on October 1 and will end on September 30.
Arnnon Geshuri, an insider at Teladoc Health, sold 2,398 shares of the company’s stock on November 28. This is just one of the many items that are relevant to this topic. In the end, each share was sold for a total of $65,585.30, bringing the price to an average of $27.35 per share. The business insider now directly owns 74,317 shares of the company’s stock, which have a value of approximately $2,032,569.95 following the completion of the transaction. The Securities and Exchange Commission was given legal documentation about the transaction, which can be viewed entirely by following the link provided in the previous sentence. The documentation was provided to the SEC. Business insiders were responsible for the sale of 3,925 shares of company stock at a total price of $105,198 during the most recent fiscal period. Individuals employed by the corporation hold 1.5% of the total number of shares in the company.
The recent events have caused several large investors to make adjustments to the amount of the company’s stock that they currently own, which brings us to the following sentence: During the third quarter, Vanguard Group Inc. increased the amount of Teladoc Health stock that is owned by 0.6%, bringing its total ownership to 100%. After making additional purchases totaling 78,859 stock units during the most recent quarter of the fiscal year, Vanguard Group Inc. now holds a total of 13,639,307 shares in the health services provider. The value of these shares on the market as of right now is $345,757,000. During the second quarter, Renaissance Technologies LLC accomplished a staggering 879.2% increase in its ownership stake in Teladoc Health. Renaissance Technologies LLC now owns 4,475,319 shares of the health services provider’s stock, which has a market value of $148,625,000 after purchasing an additional 4,018,300 shares during the most recent quarter. This brings the total number of shares owned by Renaissance Technologies LLC to 4,475,319; the State of Michigan Retirement System bought an additional 0.9% worth of Teladoc Health stock during the third quarter, bringing the total amount of the company’s shares it owns to 99.1%. The State of Michigan Retirement System now owns a total of 3,739,500 shares, with a market cap of $94,796,000. This is a result of the recent purchase of an additional 33,131 shares during the most recent quarter. Dimension Capital Singapore PTE. LTD. increased its ownership of Teladoc Health by 67.7% during the year’s second quarter. Dimension Capital Singapore PTE. LTD. now holds a total of 2,167,552 shares of the company’s stock, which has a value of $71,984,000 following the acquisition of an additional 875,344 shares during the preceding quarter.
Last but not least, Two Sigma Advisers LP increased the percentage of Teladoc Health stock owned by 46.6% during the third quarter. This certainly should not be considered the least important development. Two Sigma Advisers LP now holds 1,661,711 shares held by the health services provider due to the recent purchase of an additional 528,100 shares during the most recent quarter. The value of these shares on the market as of right now is $42,124,000. The majority of the company’s stock is owned by large financial institutions, which account for 84.14% of the total.
Teladoc Health, Inc. is a company that provides its virtual healthcare services to customers in various countries, including the United States of America. The range of services and solutions provided by the company includes protection against medical issues that are not urgent, as well as those that are episodic, chronic, and complicated. Diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health disorders are some of the conditions that fall into this category.

Tags

Leave a comment

Your email address will not be published. Required fields are marked *